Currentculinary health fundPolicy N/A

Iron sucrose (Venofer) — Intravenous Iron Replacement Coverage Criteria

This policy governs prior authorization and medical-necessity criteria for iron sucrose (Venofer and generics) intravenous therapy for iron deficiency anemia and related indications, affecting prescribers and providers seeking coverage from the payer.

Policy Summary

Payerculinary health fund

PolicyIron sucrose (Venofer) — Intravenous Iron Replacement Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJan 7, 2026

Key ActionObtain prior authorization and document specialist consultation or oral iron trial as required by the authorization criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1000 mgmax dose per 30 days

3 yrsapproval duration (HDD-CKD)

1 yrapproval duration (NDD/other)

Adults 1000 mgusual HDD-CKD course

Recommended Authorization and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indications

Covered when INDIVIDUAL meets the specified indication and dosing limits

FDA-Approved Indications: 1. Iron Deficiency Anemia in patients with Chronic Kidney Disease who are on dialysis — Approve for 3 years. 2. Iron Deficiency Anemia in patients with Chronic Kidney Disease who are not on dialysis — Approve for 1 year if the medication is prescribed by or in consultation with a nephrologist or hematologist.max 1000 mg/30 days

Dosing: Approve up to a maximum cumulative total dose of 1000 mg given intravenously per 30 days; specialist prescribing requirement for NDD-CKD.

Other Uses with Supportive Evidence

Covered when ALL of the following are met as specified below (one of A–D must be satisfied):

Other IDA criteria (A–D): Approve for 1 year if the patient meets ONE of the following options (A, B, C, or D): A) Patient meets BOTH i and ii: i. Patient has tried oral iron supplementation; AND ii. According to the prescriber, oral iron supplementation was ineffective or intolerable; OR B) According to the prescriber, patient has a condition that will interfere with oral iron absorption (examples include inflammatory bowel disease such as Crohn's disease or ulcerative colitis); OR C) Patient is currently receiving an erythropoiesis-stimulating agent (examples include epoetin alfa, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta); OR D) The medication is being requested for cancer- or chemotherapy-related anemia.max 1000 mg/30 days

Prescriber documentation required for prior oral iron trial or for conditions expected to interfere with oral absorption; dosing limit applies.

Billing and Coding

No codes provided in policymixed

No codes listed

Guideline laboratory thresholds — KDIGO examples for HDD and NDD/PDD TSAT and ferritin thresholds

KDIGO — hemodialysis-dependent (HDD) CKDInitiation of IV iron is suggested if TSAT ≤ 30% and ferritin ≤ 500 ng/mL.

KDIGO — non-dialysis-dependent (NDD) or peritoneal dialysis (PDD) CKDInitiation of oral or IV iron is suggested if TSAT < 40% and ferritin < 100 ng/mL, or if TSAT < 25% with ferritin ≥ 100 ng/mL and < 300 ng/mL.

KDIGO — profound iron deficiency (no anemia)Consider treatment with oral or IV iron when TSAT < 20% and ferritin < 30 ng/mL.

ACC/AHA — heart failure (HFrEF) guidanceRecommend IV iron for absolute iron deficiency (ferritin < 100 ng/mL) or functional iron deficiency (ferritin 100–300 ng/mL with TSAT < 20%) to improve functional status and quality of life.

Prior Authorization, Documentation, and Prescriber Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is recommended for medical benefit coverage of iron sucrose. Approvals are indication-specific and provided for the durations noted in the policy. Requests that do not meet the Recommended Authorization Criteria are not recommended for approval and may be denied.

Prior authorization recommended for medical benefit coverage of iron sucrose
Approvals follow indication-specific durations and dosing limits
Requests outside the Recommended Authorization Criteria are denial triggers

Documentation Required

Prescriber Specialty and Off-Label Dose Review

For approvals of certain indications, iron sucrose must be prescribed by or in consultation with a specialist. Requests for use at doses outside the established dosing documented in this policy will be reviewed on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist). Where approvals require a specialist, the prescriber must be a physician who specializes in the condition being treated or documentation of consultation with such a specialist must be provided.

Specialist prescriber required or documentation of specialist consultation for some indications (e.g., nephrologist, hematologist, cardiologist) per indication-specific criteria
Off-label or outside-policy dosing requests will be evaluated on a case-by-case basis by a clinician
Examples: nephrologist or hematologist for CKD indications; cardiologist or hematologist for heart failure indication

Step Therapy

Oral Iron Trial Requirement for Other IDA

For 'Other' iron deficiency anemia indications, a prior trial of oral iron is required unless the prescriber documents that oral iron was ineffective or intolerable, that the patient has a condition interfering with oral iron absorption, the patient is receiving an erythropoiesis-stimulating agent, or the request is for cancer- or chemotherapy-related anemia. Approval periods and dosing limits apply as specified in the Recommended Authorization Criteria.

For Iron Deficiency Anemia, Other: prior trial of oral iron required OR documentation of intolerance/ineffectiveness
Alternative justifications acceptable: malabsorption condition, concurrent erythropoiesis-stimulating agent, or cancer/chemotherapy-related anemia
Dosing limit: up to a maximum cumulative total dose of 1000 mg IV per 30 days
Approval duration: 1 year when criteria met

Denial Risk

Denial Trigger: Outside Listed Criteria

Requests that do not match the Recommended Authorization Criteria (including indication, required specialist involvement, documented oral iron trial or justification, or dosing limits) are not recommended for approval and are potential denial triggers.

Denial trigger: request for an indication not listed in the Recommended Authorization Criteria
Denial trigger: missing required documentation of specialist consultation when indicated
Denial trigger: no documentation of prior oral iron trial or acceptable justification for foregoing oral therapy when required
Denial trigger: requested cumulative dosing exceeds policy maximums without clinical justification

Clinical Background

Iron sucrose (Venofer) is an intravenous iron replacement product indicated for treatment of iron deficiency anemia, most commonly used in patients with chronic kidney disease (CKD). It is administered by IV infusion or slow injection; the preparation contains 20 mg elemental iron per mL and may be given as repeated treatment courses when iron deficiency persists. Dosing and total course vary by CKD status: for hemodialysis-dependent CKD, typical adult total course regimens sum to about 1000 mg, and the policy approves a maximum cumulative total of 1000 mg per 30 days. FDA‑approved CKD indications are covered with differing approval durations—3 years for patients on dialysis and 1 year for patients not on dialysis when prescribed by or in consultation with a nephrologist or hematologist. Major specialty guidelines (KDIGO, NCCN, ACC/AHA) provide context for initiating IV iron based on laboratory thresholds such as ferritin and transferrin saturation (TSAT).

OpenPayer

Iron sucrose (Venofer) — Intravenous Iron Replacement Coverage Criteria

Recommended Authorization and Medical Necessity Criteria

Billing and Coding

Prior Authorization, Documentation, and Prescriber Requirements

Clinical Background

Definitions and Drug